ABOUT US

Invivyd is a biopharmaceutical company on a mission to protect humans from serious viral diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity to provide superior protection from viral diseases, beginning with COVID-19.

Weak and short-lived mucosal immunity is a hallmark of seasonal influenza, respiratory syncytial virus, as well as SARS CoV-2, the virus that has driven the global COVID-19 pandemic.

SARS-CoV-2 continues to inflict an unacceptable burden on humankind. The antibody immune response to vaccines has helped keep us alive but leaves us at continued risk. Nonetheless, SARS-COV-2 remains a leading cause of U.S. death in 2022. To be safe and well, we require higher quality, more durable antibodies than our immune systems can produce in response to vaccination or infection.

We must close the gap between the antibodies we can make ourselves and the antibodies we need for safety, wellness and normal human functioning.

Invivyd is committed to addressing this unmet need by developing engineered antibodies superior to naturally occurring human antibodies.

Our discovery technology and platform is designed to match and overcome the challenges of viral evolution.

Our platform approach has yielded a pipeline of next generation engineered antibodies designed to provide robust and broad neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA1, BA2, BA5, and BA2.75.

Our lead product candidate for the prevention and treatment of COVID-19, adintrevimab, is ready for regulatory review and commercial readiness activities are underway as we monitor the new waves of variants of concern. In the event that a new variant emerges which is neutralized by adintrevimab, our inventory of more than 700,000 doses could be deployed in as little as 60 days after authorization.

Beyond COVID-19, we are leveraging our robust antibody discovery and development capabilities to develop therapeutic or preventative options for other respiratory viral infections, such as seasonal influenza.

Management Team

David Hering, M.B.A

David Hering, M.B.A

Chief Executive Officer & Director

Laura Walker, Ph.D.

Laura Walker, Ph.D.

Co-Founder & Chief Scientific Officer

Jill Andersen, J.D.

Jill Andersen, J.D.

Chief Legal Officer & Corporate Secretary

Becky Dabora, Ph.D.

Becky Dabora, Ph.D.

Chief Technology & Manufacturing Officer

Jane Pritchett Henderson

Jane Pritchett Henderson

Chief Financial & Business Officer

Ellie Hershberger, Pharm.D.

Ellie Hershberger, Pharm.D.

Chief Development Officer

Eric Kimble, M.B.A.

Eric Kimble, M.B.A.

Chief Commercial Officer

Board of Directors

Tamsin Berry

Partner, Population Health Partners

Marc Elia

Founder and Chief Investment Officer, M28 Capital Management L.P., Chairperson of the Board

David Hering, M.B.A

Chief Executive Officer & Director

Tom Heyman

Former President, Johnson & Johnson Development Corporation (JJDC)

Terry McGuire

Partner, Polaris Partners

Clive A. Meanwell, M.D.

Executive Chair and Co-founder, Population Health Partners

Redonda Miller, M.D., MBA

President, The Johns Hopkins Hospital

Michael Wyzga

President, MSW Consulting, Inc.